Fluorouracil (F), Adriamycin (A), and cisplatin (P) (FAP): combination chemotherapy of advanced esophageal carcinoma

Cancer. 1983 Sep 15;52(6):974-7. doi: 10.1002/1097-0142(19830915)52:6<974::aid-cncr2820520607>3.0.co;2-#.

Abstract

Twenty-one patients with advanced epidermoid carcinoma of the esophagus were treated with a combination of 5-fluorouracil (F) 600 mg/m2 day 1 and day 8; Adriamycin (A) 30 mg/m2 day 1; and cisplatin (P) 75 mg/m2 day 1 (FAP) with hydration and mannitol-induced diuresis. Each course was repeated every 4 weeks. All 21 patients are evaluable for response: 7 patients had an objective response (33%). Two of these responses were complete remissions according to negative endoscopic and pathologic results; five patients had a partial response; all 7 responding patients had metastasis prior to treatment. Median survival of the 21 patients was 8 months. Median survival of 9 months for responders is superior to 4.5 months for nonresponders. No severe myelosuppression or nephrotoxicity was observed. This FAP regimen is useful in the treatment of advanced esophageal tumors.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • Adult
  • Aged
  • Antineoplastic Combined Chemotherapy Protocols*
  • Carcinoma, Squamous Cell / drug therapy*
  • Carcinoma, Squamous Cell / mortality
  • Cisplatin / administration & dosage*
  • Doxorubicin / administration & dosage*
  • Drug Therapy, Combination
  • Esophageal Neoplasms / drug therapy*
  • Esophageal Neoplasms / mortality
  • Fluorouracil / administration & dosage*
  • Humans
  • Middle Aged
  • Time Factors

Substances

  • Doxorubicin
  • Cisplatin
  • Fluorouracil

Supplementary concepts

  • FAP protocol